- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.04. | Spotlight on Hepatitis B: New report examines the disease's clinical trial landscape in 2025 | ||
| 22.04. | DAAN Biotherapeutics and GC Cell agree on CAR-T, CAR-NK therapies | ||
| 22.04. | KKR offers $1.2bn to buy Swedish life sciences group Biotage | ||
| 22.04. | Roche announces $50bn US investment in pharma and diagnostics | ||
| 21.04. | FDA grants breakthrough status to uniQure's Huntington's disease therapy | ||
| 21.04. | UK's MHRA authorises GSK's Blenrep for multiple myeloma treatment | ||
| 21.04. | Sanofi and Regeneron's dupilumab approved by FDA for urticaria | ||
| 18.04. | Eli Lilly and BigHat Biosciences ink AI antibody discovery deal | ||
| 17.04. | Eli Lilly's shares up as oral GLP-1RA scores in first Phase III trial | ||
| 17.04. | FDA to review Regeneron's sBLA for aflibercept injection 8mg | ||
| 17.04. | Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline | ||
| 17.04. | Big pharma pushes for European policy change as tariffs loom | ||
| 17.04. | FDA approves Neurelis' nasal spray for seizures | ||
| 17.04. | ACIP recommends GSK's RSV vaccine for at-risk adults 50 to 59 | ||
| 16.04. | Trump order eases Medicare price negotiation for small molecule drugs | ||
| 16.04. | Glycomine raises $115m to advance rare disease therapy into Phase IIb | ||
| 16.04. | WHO member states agree on treaty to fight future pandemics | ||
| 16.04. | Podcast: What's next for the pharma tariffs? | ||
| 16.04. | The GLP-1 drug shortage is over. What's next for the compounders? | ||
| 16.04. | EC authorises Eisai and Biogen's lecanemab for Alzheimer's | ||
| 16.04. | Mural shuts down lead programme and slashes 90% of staff | ||
| 16.04. | Irish pharmaceutical exports to US soar amid tariff concerns | ||
| 16.04. | The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033 | ||
| 16.04. | Boehringer and Cue Biopharma to develop autoimmune therapies | ||
| 15.04. | Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts? |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .